At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 274 enrolled
Drug / intervention
KHK4083 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects With Moderate to Severe Atopic Dermatitis (AD)
In Brief
A Phase 2 clinical trial evaluating KHK4083 and Placebo for Atopic Dermatitis. Completed, enrolled 274 participants across 58 sites in 4 countries.
Detailed Summary
A Phase 2, multicenter, randomized, placebo-controlled, double-blind, parallel-group study for subjects with moderate to severe AD whose disease cannot be adequately controlled with topical medications or for whom topical treatment is medically inadvisable.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesCanada, Germany, Japan, United States
CollaboratorsKyowa Kirin Co., Ltd.
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedOct 2018
Enrollment StartOct 2018
Primary CompletionFeb 2020
Study CompletionNov 2020
TodayJul 2026
First PostedOct 11, 2018
Enrollment StartOct 22, 2018
Primary CompletionFeb 6, 2020
Study CompletionNov 12, 2020
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 7.7 years ago
Interventions
KHK4083drug
Anti-OX40 Monoclonal Antibody KHK4083
Placebodrug
Matching placebo